David Roche of Quantum Strategy says a weaker dollar will drive 10-year yields to 5.5%, which will threaten the dollar's ...

For years, Roche has been increasing medicine production in the United States. That could pay off for the drug maker as ...

Swiss drugmaker Roche is petitioning the U.S. government in direct talks for import tariff exemptions, arguing the products ...

Seductive Reasoning,” a flop that preceded the Roches’ debut, has a fluctuating sonic palette, contributions from Paul Simon ...

Swiss drugmaker Roche said on Thursday its first-quarter sales rose a forecast-beating 7% driven by breast cancer drug Phesgo ...

Roche posted higher-than-expected first-quarter sales, driven by robust demand for its key drugs, as the company takes active ...

Positive recommendation based on clinical, real-world and bioequivalence data supporting feasibility and safety of Phesgo's ...

The American Association for Cancer Research’s annual conference continued Monday with Roche offering a postmortem for its ...

The move will also create 12,000 new jobs across the United States, with 6,500 in construction and 1,000 at “new and expanded ...

Roche’s exposure to the tariffs is mostly limited to four medicines, three of which it already produces in the U.S., ...

Roche posted a Q1 revenue beat, with strong contributions from Phesgo, Xolair, and Polivy, despite larger products lagging.

April 22 (UPI) -- Biotechnology giant Roche said it will invest $50 billion into the United States over the next five years.